(NASDAQ:AVGR) reached a new 52-week low during trading on Thursday.
AVGR has been the topic of a number of research reports.
Avinger Inc Cmn (NASDAQ:AVGR) has average revenue estimates of $2.8 Million, compared to low analyst estimates of $2.8 Million and high estimates of $2.8 Million for the current quarter. Zacks Investment Research raised shares of Avinger from a "hold" rating to a "buy" rating in a research note on Tuesday, June 20th. The company has a 50 day moving average price of $0.47 and a 200-day moving average price of $1.15. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock.
On the other hand the company has Relative Strength Index (RSI 14) of 27.22 along with Average True Range (ATR 14) of 0.06, Consequently Avinger Inc Cmn (NASDAQ:AVGR)'s weekly and monthly volatility is 16.50%, 10.38% respectively. (NASDAQ:AVGR) opened at $0.4, and ended -29.63% lower at $0.28.
Several equities research analysts recently commented on the stock.
Avinger, Inc. (AVGR) failed to surprise the stock market in its last reported earnings when it earned -$0.51 a piece versus the consensus-estimated -$0.47.
Avinger Inc Cmn (NASDAQ:AVGR)'s revenue estimates for the current quarter are $2.8 Million according to 1 number of analysts, for the current quarter the company has high revenue estimates of $2.8 Million in contradiction of low revenue estimates of $2.8 Million. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & worldwide copyright law.
After the recent decrease, investors may also look to see if the stock has entered oversold territory and could possibly ripe for a reversal. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). Institutional investors own 61.11% of the company's stock. IL increased its stake in Avinger by 5.0% in the first quarter. Blair William IL has an ownership of 73,900 stocks of the medical device firms shares valued at $188,000 after scooping up an extra 3,500 stocks in the previous period. RMB Capital Management LLC acquired a new position in shares of Avinger during the fourth quarter valued at about $1,123,000. Finally, FMR LLC acquired a new position in Avinger during the fourth quarter valued at approximately $5,772,000. Broadfin Capital purchased a fresh position in Avinger during the Q1 valued about $950,000. The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.